


Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2025*

POTENTIAL APPROVALS US/EU		PLANNED SUBMISSIONS US/EU		POTENTIAL CLINICAL DATA PRESENTATIONS*	
✓ US SIMPONI (golimumab)	✓ EU Pediatric Ulcerative Colitis (PURSUIT 2)	✓ US IMAAVY (nipocalimab)	✓ EU Generalized Myasthenia Gravis (Vivacity MG3)	✓ US nipocalimab	✓ US INLEXZO (gemcitabine intravesical delivery system)
✓ EU Pediatric Crohn's Disease (UNITI JR)	✓ US STELARA (ustekinumab)	✓ US SPRAVATO (esketamine)	Treatment Resistant Depression monotherapy (TRD4005)	✓ EU TREMFYA (guselkumab)	✓ US Non Muscle Invasive Bladder Cancer (SunRISe-1)
✓ US TREMFYA (guselkumab)	✓ EU Ulcerative Colitis Subcutaneous Induction (ASTRO)	✓ US CAPLYTA (lumateperone)	Adjunctive Treatment for Major Depressive Disorder	✓ EU TREMFYA (guselkumab)	✓ US AKEEGA (niraparib/abiraterone)
✓ EU Crohn's Disease Subcutaneous Induction (GRAVITI)	✓ US TREMFYA (guselkumab)	✓ US DARZALEX (daratumumab)	✓ EU Smoldering Multiple Myeloma (AQUILA)	✓ EU TREMFYA (guselkumab)	✓ EU M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)
✓ US TREMFYA (guselkumab)	Pediatric Psoriasis (PROTOSTAR)	✓ US DARZALEX (daratumumab)	✓ EU Frontline multiple myeloma transplant ineligible (CEPHEUS)	✓ US TREMFYA (guselkumab)	✓ EU RYBREVANT / LAZCLUZE
✓ US TREMFYA (guselkumab)	Pediatric Juvenile Psoriatic Arthritis	✓ US INLEXZO (gemcitabine intravesical delivery system)	Non Muscle Invasive Bladder Cancer (SunRISe-1)	✓ US STELARA (ustekinumab)	✓ US Non Small Cell Lung Cancer (MARIPOSA Final OS)
✓ EU Crohn's Disease (GALAXI)	✓ US TREMFYA (guselkumab)	✓ US RYBREVANT (amivantamab)	✓ EU Subcutaneous (PALOMA-3)	✓ EU STELARA (ustekinumab)	✓ US TREMFYA (guselkumab)
✓ EU Ulcerative Colitis (QUASAR)	✓ US IMBRUVICA (ibrutinib)	✓ US icotrokinra	✓ EU Psoriasis (ICONIC)	✓ US icotrokinra	✓ EU Psoriasis (ICONIC-LEAD)
	✓ US IMAAVY (nipocalimab)	✓ US Psoriasis (ICONIC)		✓ EU icotrokinra	✓ EU Psoriasis (ICONIC-TOTAL)
	Generalized Myasthenia Gravis Pediatrics (VIBRANCE MG)			✓ EU icotrokinra	✓ EU Psoriasis (ICONIC-Advance1/2)
	✓ US AKEEGA (niraparib/abiraterone)	✓ US aticaprant	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	✓ US aticaprant	Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)
	M1 Metastatic Castration-Sensitive Prostate Cancer (AMPLITUDE)	✓ US RPGR Gene Therapy		✓ US RPGR Gene Therapy	Retinitis Pigmentosa (LUMEOS)
		✓ US TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs (MajesTEC-3)	✓ US TECVAYLI (teclistamab)	Multiple Myeloma 1-3PLs (MajesTEC-3)
✓ = Achieved					



In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.